Spots Global Cancer Trial Database for Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Official Title: Exploration of the Neuromuscular Mechanisms Associated With Sunitinib Related Fatigue

Study ID: NCT01740154

Conditions

Fatigue

Recurrent Renal Cell Cancer

Stage IV Renal Cell Cancer

Interventions

transcranial magnetic stimulation

electromyography

survey administration

sunitinib malate

Study Description

Brief Summary: The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are participating in this research study. The questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of physical measurements for fatigue will be performed before the first dose of sunitinib and again (4) weeks later to see if there are any changes in physical level of fatigues

Detailed Description: PRIMARY OBJECTIVES: I. To determine the mechanisms associated with sunitinib related fatigue by recording EMG signals during a submaximal elbow contraction, twitch force and TMS prior to and at the end of 4 weeks of sunitinib in metastatic RCC patients. OUTLINE: Patients receive sunitinib malate orally (PO) daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28. .